Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?
about
Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 diseaseCCR8 on human thymocytes functions as a human immunodeficiency virus type 1 coreceptor.Tyrosine sulfation of CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and temporal sequence.Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusionSpecific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120Statins disrupt CCR5 and RANTES expression levels in CD4(+) T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1Hierarchical kernel mixture models for the prediction of AIDS disease progression using HIV structural gp120 profiles.Simian immunodeficiency virus utilizes human and sooty mangabey but not rhesus macaque STRL33 for efficient entry.Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domainsUse of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells.Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis.Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo.Human peripheral blood T cells, monocytes, and macrophages secrete macrophage inflammatory proteins 1alpha and 1beta following stimulation with heat-inactivated Brucella abortus.Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate.Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C.Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells.Transcriptional regulation of the chemokine co-receptor CCR5 by the cAMP/PKA/CREB pathway.Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals.Sequential tyrosine sulfation of CXCR4 by tyrosylprotein sulfotransferases.Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4.Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.CXCR4-dependent infection of CD8+, but not CD4+, lymphocytes by a primary human immunodeficiency virus type 1 isolate.Physiological coreceptor use by dual-tropic HIV-1: one plus one equals one.Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course.CCR5 and CXCR4 usage by non-clade B human immunodeficiency virus type 1 primary isolates.
P2860
Q24524292-BEA10B82-2629-4A27-916C-E5A08190B827Q24525316-04D8A135-9CBA-448F-8F2F-19EF4F39A820Q24534959-DCD665BD-3D0F-420D-9FC3-23C751094A22Q24678540-00AC50C0-5263-4012-9659-BE112AEDC4A9Q28344310-D5A29C76-1289-49F7-A07E-44157F2F5535Q33285482-4429432D-1252-41A3-BFD4-44EF79BD22C3Q33766727-732540BD-CC0C-4518-94EA-0C945B7C2CD2Q33787066-5B8A6DB3-0FD1-4C63-AD30-0CAC9098A5E9Q33796067-A25ABCCC-5783-4CE9-9148-10AA5CC81F09Q33808728-96B8CA45-C672-41BD-B742-8BDD8FE96C5FQ33808920-FBA10547-BF2E-4591-BA37-90C98A0C8048Q33813025-270D45AF-29B0-4365-806E-2672635EF1EFQ33815285-86D0874B-5F77-498E-B726-57C76E9EFDBFQ33822395-0C14A90E-CB85-4920-B9EA-50F5E281A7A3Q33858164-88C564A7-F79E-493B-B656-5ACD5677E2CEQ34007794-77F04025-660B-4452-857E-5E0BCBC2B4AEQ34340428-D5BA1A78-026B-441B-A030-076F7394A3F9Q34425169-91605027-FDB3-4AB7-A0FE-9EB21D647BE8Q34553676-6CFE58BE-D15F-4210-932B-1BD828D02B9FQ34781878-F522DFDD-E0D8-4D09-ADDE-932DE541E1E8Q34975941-91DE8488-D4F3-46D0-A53D-DB2A18E3E94DQ34996958-9C19E925-434A-44A6-BE68-CE9E2DCB1F10Q35148038-2965A52D-4FF3-4ED3-933F-01627B037546Q35922555-83F7A685-56FE-4C9D-A4E8-D87EE8FAA7CDQ36371505-B04FE9AF-1A80-49FA-86A3-1D38CA3BB0AFQ36509765-C801ED3F-A378-4212-B12B-8F5B0E247079Q36510410-BE011284-5C52-41A1-92E4-B38CB37919FAQ37143965-6D62720F-7689-4905-BFF5-E9C6E8DE2846Q37583423-694CEC05-C126-43EA-B18F-4AD264C2B200Q37596456-D80FAD4C-3E3B-4CFE-A4D9-A11BF91BEB91Q37596922-55C683EF-23EB-45A4-9E71-2DE0AC4BADF4Q39406629-0CA12A99-8F68-459F-95AE-9DA1B8D39111Q39605628-DA70B422-75ED-4372-92A0-F9C7361123D5Q39682772-3B0472FD-D40E-46E0-8CF8-74A55DFBDDAC
P2860
Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Will multiple coreceptors need ...... deficiency virus type 1 entry?
@ast
Will multiple coreceptors need ...... deficiency virus type 1 entry?
@en
type
label
Will multiple coreceptors need ...... deficiency virus type 1 entry?
@ast
Will multiple coreceptors need ...... deficiency virus type 1 entry?
@en
prefLabel
Will multiple coreceptors need ...... deficiency virus type 1 entry?
@ast
Will multiple coreceptors need ...... deficiency virus type 1 entry?
@en
P2860
P1433
P1476
Will multiple coreceptors need ...... deficiency virus type 1 entry?
@en
P2093
P2860
P304
P577
1999-04-01T00:00:00Z